Development and Validation of a Simplified Prognostic Score in SCLC.

ABSTRACT

INTRODUCTION: This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing by their overall survival (OS). METHODS: The SPS was developed exploring the Montpellier University Hospital retrospective database of 401 patients over a 16-year period. All patients had received etoposide - platinum-based chemotherapy as first-line treatment. The SPS development took into account significant determinants of OS in the Cox model, weighted by their regression ß coefficients. Validation of the consequent SPS has been done separately in a combined population of 213 patients accrued from two different published trials (NCT03059667 and NCT00930891). RESULTS: The significant independent determinants of OS included the following (1) American Joint Committee on Cancer TNM stage IV (hazard ratio [HR] 2.52; 95% confidence interval [CI] 1.91-3.33); (2) Eastern Cooperative Oncology Group performance status greater than 1 (HR 2.27; 95% CI 1.79-2.87); (3) the presence of liver metastases (HR 1.66; 95% CI 1.29-2.15); and (4) neutrophil-to-lymphocyte ratio greater than 4 (HR 1.39; 95% CI 1.11-1.92). The SPS generated with these four variables, segregated three groups (good, intermediate, and poor prognosis) with respective median OS of 26.9 months (95% CI 20.1-38.9), 11.5 months (95% CI 9.8-13.0), and 6.8 months (95% CI 5.8-8.3; log-rank p < 10-4). Harrell's C statistic estimate was 0.68 ± 0.012, suggesting goodness of calibration. In the validation cohort, the SPS segregated the aforementioned three subgroups in a nearly similar manner, with respective median OS 27.2, 12.3, and 8.6 months (log-rank p < 10-3; Harrell's C statistic 0.58 ± 0.02). CONCLUSIONS: The SPS is easy to calculate in real-life practice and efficiently discriminates three populations with different prognoses. This study deserves further validation of this score in patients with SCLC receiving immunochemotherapy.